Double-blind prospective randomized comparison of interferon gamma-1b versus placebo after autologous stem cell transplantation

Acta Haematologica

Volumn 108, Issue 2, 2002, Pages 66-73

  Koziner, Benjamin ^a,b   Dengra, C ^a   Cisneros, M ^a   Glancszpigel, R ^a  

^a Clinica Independencia Buenos Aires   (Argentina)

^b NONE   (Argentina)

Author keywords

Autologous stem cell transplantation; Hodgkin's disease; Interferon gamma 1b; Multiple myeloma; Non Hodgkin's lymphoma; Solid tumors

Indexed keywords

CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; MELPHALAN; PLACEBO; RECOMBINANT GAMMA INTERFERON; THIOTEPA;

ADULT; ARTHRALGIA; ARTICLE; AUTOTRANSPLANTATION; BLOOD AUTOTRANSFUSION; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FEVER; FOLLOW UP; HEADACHE; HODGKIN DISEASE; HUMAN; HYPERSALIVATION; INJECTION PAIN; LEG PAIN; LEUKOCYTE COUNT; MALE; MULTIPLE MYELOMA; MUSCLE WEAKNESS; MYALGIA; NEUTROPHIL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SOLID TUMOR; SOMNOLENCE; STEM CELL TRANSPLANTATION; SURVIVAL TIME; SWEATING; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERFERON-GAMMA, RECOMBINANT; MALE; MIDDLE AGED; NEOPLASMS; PLACEBOS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0036375296     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000064745     Document Type: Article

References (28)

1. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity
2. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma)
3. Recombinant interferon-gamma induces interleukin 2 receptors on human peripheral blood monocytes
4. Recombinant interferon-gamma increases HLA-DR synthesis and expression
5. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells
6. Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation
7. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia
8. Nonparametric methods of estimating survival functions
9. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
10. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
11. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial
12. Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies
13. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors
14. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-α in lymphoma patients post-autologous marrow or stem cell transplantation
15. The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission
16. Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma
17. Cellular immunotherapy following autologous hematopoietic progenitor cell transplantation
18. Cyclosporine-induced graft-versus-host disease following autologous bone marrow transplantation in acute myeloid leukaemia
19. Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer
20. Autologous graft vs. host disease (AGVHD) as immune therapy after high-dose chemotherapy (HDC) for metastatic breast cancer (MBC): Medium-term follow up and comparison with historical controls
21. Cyclosporine A (CsA) induces autologous graft vs. host disease (AGVHD) following high dose chemotherapy (HDC) supported with peripheral blood progenitor cell (PBPC) infusions alone
22. Immune modulation in autologous bone marrow transplantation: Cyclosporine and gamma-interferon trial
23. Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin-2 after autologous bone marrow transplantation
24. The phenotype and reconstitution of immunoregulatory T cell subsets after T cell-depleted allogeneic and autologous bone marrow transplantation
25. Altered immunologic reconstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone marrow support
26. Regeneration of functional and activated NK and T sub-subset cells in the marrow and blood after autologous bone marrow transplantation: A prospective phenotypic study with 2/3-color FACS analysis
27. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow
28. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer